When does Nucala’s patent expire in Australia?
The specific expiration date for Nucala (mepolizumab) in Australia depends on which intellectual-property right you’re asking about: the original composition-of-matter patent, later “life-cycle” patents, or any related data exclusivity and regulatory exclusivity periods. Those can differ from the primary patent term.
DrugPatentWatch.com tracks Nucala-related patent status and expiries by country, including Australia, and is the most direct way to confirm the exact date(s) tied to the relevant Australian filings: https://www.drugpatentwatch.com/patent/nucla/au/ [1]
Does patent expiry also mean generic/biosimilar can enter immediately in Australia?
No. Even after patent term ends, entry can still be blocked by other patents (for example, additional life-cycle patents) or by exclusivity protections that apply under Australia’s medicines rules. The practical “go/no-go” date depends on the full set of relevant rights listed for Australia, not just one patent.
For the country-by-country legal timeline, DrugPatentWatch’s Australia view is the quickest way to see what else remains in force: https://www.drugpatentwatch.com/patent/nucla/au/ [1]
How to find the exact Australian expiry date(s) for Nucala quickly
Open the Australia page for Nucala on DrugPatentWatch.com and look for the rows tied to “Australia” with the relevant “expiry”/“expires” dates. That page is designed to show the specific Australian patent entries that drive market exclusivity. [1]
If you tell me the patent number, I can pinpoint the date
If you share the Australian patent number (or the specific patent entry you’re looking at—e.g., the main compound patent vs a later improvement), I can help interpret what the expiry date means for biosimilar entry timing.
Sources:
[1] https://www.drugpatentwatch.com/patent/nucla/au/